Serum Cytokines in Metastatic Melanoma Patients Treated with an Autologous Tumor Vaccine

Cancer Biotherapy and Radiopharmaceuticals

Volumn 18, Issue 6, 2003, Pages 879-886

  Schiltz, Patric M ^a   Dillman, Robert O ^a  

^a Hoag Memorial Presbyterian Hospital   (United States)

Author keywords

Active specific immunotherapy; Interleukin 10; Interleukin 2; Serum cytokines

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MELANOMA VACCINE; TUMOR VACCINE;

ACTIVE IMMUNIZATION; ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL;

EID: 0348199327     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497803322702842     Document Type: Article

References (27)

1. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216:462.
2. Berd D, Maguire HC Jr, McCue P, Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 1990;8:1858.
3. Miller K, Abeles G, Oratz R, et al. Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine. Cancer 1995;75:495.
4. Rosenberg SA. A new era of cancer immunotherapy: Converting theory to performance. CA Cancer J Clin 1999;49:70.
5. Safa MM, Foon KA. Adjuvant immunotherapy for melanoma and colorectal cancer. Semin Oncol 2001;28:68.
6. Weber JS, Aparicio A. Oncol Novel immunologic approaches to the management of malignant melanoma. Curr Opin Oncol 2001;13:124.
7. Dillman RO, Nayak SK, Barth NM, et al. Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma. Cancer Biother Radiopharm 1998;13:165.
8. Dillman RO, Nayak SK, Beutel L. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993;14:65.
9. Nayak SK, Dillman RO. Establishment of multiple tumor cell lines from a patient with melanoma: A simple method to control fibroblast growth. Clin Biotechnol 1991;3:237.
10. Dillman RO, DeLeon C, Beutel LD, et al. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 1995;39:115.
11. Ihn H, Sato S, Fujimoto M, et al. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995;287:193.
12. Bohlen H, Kessler M, Sextro M, et al. Poor clinical outcome of patients with Hodgkin's disease and elevated interleukin-10 serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 2000;79:110.
13. Grimm EA, Smid CM, Jack Lee J, et al. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy. Clin Cancer Res 2000;6:3895.
14. Hsu DH, de Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRFI. Science 1990;250:830.
15. Vieira P, de Waal Malefyt R, Dang MN, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991;88:1172.
16. Tago K, Tosato G. IL-10 inhibits T-cell proliferation and IL-2 production. J Immunol 1992;148:1143.
17. Del Prete G, De Carli M, Almerigogna F, et al. Human IL-10 is produced by both type I helper (Th1) and type 2 helper (Th2) T-cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993;150:353.
18. Ralph P, Nakoinz I, Sampson-Johannes A, et al. IL-10, T-lymphocyte inhibitor of human blood cell production of IL-1 and tumor necrosis factor. J Immunol 1992;148:808.
19. Tripp CS, Wolf SF, Unanue ER. Interleukin-12 and tumor necrosis factor alpha are co-stimulators of interferon-gamma production by natural killer cells in severe combined immuno-deficiency mice with listeriosis, and interleukin-10 is a physiologic antagonist. Proc Natl Acad Sci USA 1993;90:3725.
20. De Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;74:1209.
21. De Waal Malefyt R, Haanen J, Spits H, et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991;174:915.
22. De Smedt T, Van Mechelen M, De Becker G, et al. Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 1997;27:1229.
23. Huang S, Xie K, Bucana CD, et al. Interelukin-10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis. Clin Cancer Res 1996;2:1969.
24. Giovarelli M, Musiani P, Modesti A, et al. Local release of IL-10 transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor rejection and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol 1995;155:3112.
25. Sun H, Jackson MJ, Kundu N, Fulton AM. Interelukin-10 gene transfer activates interferon-gamma and the interferon-gamma-inducible genes Gbp-1/Mag-1 and Mig-1 in mammary tumors. Int J Cancer 1999;80:624.
26. Sun H, Gutierrez P, Jackson MJ, et al. Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10. J Immunother 2000;23:208.
27. Sato T, McCue P, Masuoka K, et al. Interleukin-10 production by human melanoma. Clin Cancer Res 1996;2:1383.